NCT05468203View on ClinicalTrials.gov

PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care

PHASE3RecruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

March 1, 2027

Conditions
Acute Kidney Injury
Interventions
DRUG

Dapagliflozin 10mg Tab

Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days

DRUG

Placebo

Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days

Trial Locations (2)

3084

RECRUITING

Austin Health, Heidelberg

3350

NOT_YET_RECRUITING

Grampians Health, Ballarat

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

Australian and New Zealand Intensive Care Society Clinical Trials Group

NETWORK

lead

The George Institute

OTHER

NCT05468203 - PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care | Biotech Hunter | Biotech Hunter